期刊文献+

雷替曲塞联合长春瑞滨在晚期三阴性乳腺癌中的临床研究 被引量:5

Clinical research on the raltitrexed -vinorelbine combination to treat patients with advanced triple -negative breast cancer
下载PDF
导出
摘要 目的评价雷替曲塞(raltitrexed)联合长春瑞滨(vinorelbine)治疗蒽环及紫杉类耐药的晚期三阴性乳腺癌(TNBC)的疗效和毒副反应。方法选取21例对蒽环及紫杉类耐药的晚期TNBC患者,采用雷替曲塞3mg/m^2,静脉滴注,d1;长春瑞滨25mg/m^2,静脉滴注,d1、8。3周为一个疗程,2个疗程后评价患者的疗效、KPS评分等,每周期化疗后评价毒副反应。结果完全缓解(CR)2例,部分缓解(PR)6例,稳定(SD)6例,进展(PD)7例,总有效率(RR)为38.1%,疾病控制率(DCR)为66.7%。中位疾病进展时间(TTP)为5个月。化疗前后KPS评分差异有统计学意义(P〈0.05)。无化疗相关死亡病例,毒副反应主要为中性粒细胞减少(16例)、血小板减少(6例)、胃肠道反应(8例)、脱发(17例)等。结论雷替曲塞联合长春瑞滨对蒽环及紫杉类耐药的晚期TNBC有较好的疗效,毒副反应可耐受,是可以选择的治疗方案之一。 Objective To evaluate the clinical efficacy and toxicity of the rahitrexed - vinorelbine combination on patients with advanced triple - negative breast cancer resistant to anthracyelines and taxanes. Methods A total of 21 patients were included into the current study, who suffered with advanced triple - negative breast cancer and became resistant to anthracyclines and taxanes. All patients were administrated with raltitrexed (3 mg/m^2, ivgtt, d1 ) and vinorelbine (25 mg/m^2 , ivgtt, d1 and 8) for six weeks. Then, their efficacy and Karnofsky performance status (KPS) scores were assessed, while toxic and adverse reactions were recorded every three weeks. Results Complete remission (CR) was seen in two patients, partial remission (PR) in six patients, stable disease (SD) in six patients, and progression disease (PD) in seven patients. The overall response rate (RR = CR + PR) was 38.1%, while the clinical benefit rate (DCR = CR + PR + SD) was 66.7%. The median time to progression (TTP) was 5.0 months. Their KPS scores before and after chemotherapy were statistically significant (P 〈 0.05 ). There was no death related to chemotherapy. Untoward reactions ineluded leucopenia ( 16 patients), thrombocytopenia (6), gastrointestinal reactions (8) and alopecia ( 17 ). Conclusion The raltitrexed - vinorelbine combination is effective and well tolerated for patients with advanced triple - negative breast cancer who are resistant to anthracyclines and taxanes, which can be applied as one of practical regimens.
出处 《徐州医学院学报》 CAS 2015年第4期269-271,共3页 Acta Academiae Medicinae Xuzhou
基金 江苏省卫生厅医学科技发展基金会临床肿瘤学科研课题(P200942) 徐州医学院课题(08KJ53)
关键词 晚期三阴性乳腺癌 雷替曲塞 长春瑞滨 化学治疗 advanced triple- negative breast cancer raltitrexed vinorelbiue chemotherapy
  • 相关文献

参考文献11

  • 1Suba Z. Triple -negative breast cancer risk in women is defined by the defect of estrogen signaling: preventive and therapeutic im- plications [ J]. Oneo Targets Ther, 2014,7 : 147 - 164.
  • 2Dent R, Hanna WM, Trudeau M, et al. Pattern of metastatic spread in triple - negative breast cancer [ J ~. Breast Cancer Res Treat, 2009,115(2) :423 -428.
  • 3Joensuu H, Gligorov J. Adjuvant treatments for triple - negative breast cancers [ J 1. Ann Oncol, 2012,23 (6) :40 - 45.
  • 4lsakoff SJ. Triple - negative breast cancer: role of specific chemo- therapy agents ~ J]. Cancer J, 2010,16 ( 1 ) :53 - 61.
  • 5冉凤鸣,臧爱华.长春瑞滨联合吉西他滨治疗晚期乳腺癌的临床观察[J].现代肿瘤医学,2009,17(3):487-488. 被引量:7
  • 6Padhani AR, Ollivier L. The RECIST ( Response Evaluation Cri- teria in Solid Tumors) criteria: implications for diagnostic radiolo- gists [J]. Br J Radiol, 2001, 74(887):983-986.
  • 7Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013 [J]. CA Cancer J Clin, 2013,63 ( 1 ) : 11 - 30.
  • 8李朝辉,张文,周立中.雌激素受体、孕激素受体表达与乳腺癌新辅助化疗疗效及预后的关系[J].肿瘤研究与临床,2012,24(4):269-271. 被引量:7
  • 9Hudis CA, Gianni L. Triple- negative breast cancer: an unmet medical need [ J ]. Oncologist, 2011,16 ( Suppl 1 ) : 1 - 11.
  • 10McDonald AC, Vasey PA, Adams L, et al. A phase I and phar- macokinetic study of LY231514, the multitargeted antifolate [ J ]. Clin Cancer Res, 1998,4 ( 3 ) :605 - 610.

二级参考文献18

  • 1徐兵河.乳腺癌[J].癌症进展,2004,2(1). 被引量:32
  • 2Rivera E,Valero V, Arun B, et al. Phase Ⅱ study of peylated liposomal doxorubicin in combination with gemcitabine in patients with metastatic breast cancer[ J]. Clin Oncol,2003,21 (17) :3249.
  • 3Silvestris N,D3.prile M,Andreola G,et al. Rationale for the use of gemeitabine in breast cancer (Review) [J]. Iht J Oncol,2004,24 (2) :389 -398.
  • 4Martin M, Ruiza, Munoz M, et al. Gemcitabine plus vinorelbine versus vinorelbine monotherapy in patients with metastatic breast cancer previously treated with anthracyclines and taxanes:final results of the phase Ⅲ Spanish Breast Cancer Research Group (GEICAM) trail[ J ]. Lancet Onco1,2007,8 ( 3 ) : 187 - 189.
  • 5Sanal SM, Gokmen E, Karabulut B, et al. Gemcitabine and vinorelbine combination in patients with metastatic breast cancer [ J].Breast J,2002,8(3) :171 -176.
  • 6Gianni L, Eiermann W, Semiglazov V, et al. Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2- positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort. Lancet. 2010. 375:377-384.
  • 7Byrski T, Huzarski T, Dent R, et al. Response to neoadjuvant therapy with cisplatin in BRCAl-positive breast cancer patients. Breast Cancer Res Treat, 2009, 115:359-363.
  • 8Perez EA, Romond EH, Suman V J, et al. Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breastcancer: joint analysis of data from NCCTG N9831 and NSABP B-31. J Clin Oncol, 2011, 29:3366-3373.
  • 9GreeneFL,PageDL,FlemingID.AJCC肿瘤分期手册.6版.北京:中国医药科技出版社,2009:43.
  • 10吴剑斌.乳腺癌新辅助化疗不同方案近期疗效的比较分析.福州:福建医科大学,2009.

共引文献12

同被引文献32

  • 1中国抗癌协会乳腺癌专业委员会.中国抗癌协会乳腺癌诊治指南与规范(2011版)[J].中国癌症杂志,2011,21(5):367-417. 被引量:269
  • 2Galano G,Caputo M,Tecce MF,et al.Efficacy and toler- ability of vinorelbine in the cancer therapy[J].Curr Drug Saf,2011,6(3):185-193.
  • 3Ferrero JM,Chamorey E,Magn 6 N,et al.The raltitrexed- vinorelbine combination:a phase I pharmacokinetic and pharmacodynamic trial in advanced breast cancer[J].Can- cer Chemother Pharmacol,2002,50(6):459-464.doi:10.1007/s00280-002-0519-2.
  • 4Vokes EE,Goh BC,Bertucci D,et al.A Phase I study of raltitrexed and paclitaxel given every 3 weeks to patients with solid tumors[J].Cancer,1999,86(3):528-532.
  • 5Judson IR.'Tomudex'(raltitrexed)development:preclinical,phase I and II studies[J].Anticancer Drugs,1997,8(Suppl 2):S5-S9.
  • 6Dong Y,Wang X,Zhang J,et al.Raltitxexed's effect on the development of neural tube defects in mice is associated with DNA damage,apoptosis,and proliferation[J].Mol Cell Biochem,2015,398(1-2):223-231.doi:10.1007/si1010-014-2222-0.
  • 7Wang J,Xu B,Yuan P,et al.Capecitabine combined with docetaxel versus vinorelbine followed by capecitabine main- tenance medication for first-line treatment of patients with advanced breast cancer:Phase 3 randomized trial[J].Cancer,2015,121(19):3412-3421.doi:10.1002/cncr.29492.
  • 8Li M,Fan Y,Li Q,et al.Vinorelbine plus platinum in patients with metastatic triple negative breast cancer and prior anthracycline and taxane treatment[J].Medi- cine(Baltimore),2015,94(43):el928.doi:10.1097/MD.0000000000001928.
  • 9Andreopoulou E,Sparano JA.Chemotherapy in patients with anthracycline-and taxane-pretreated metastatic breast cancer:an overview[J].Curr Breast Cancer Rep,2013,5(1):42-50.DOI:10.1007/s12609-012-0097-1.
  • 10Xu YC,Wang HX,Tang L,et al.A systematic review of vinorelbine for the treatment of breast cancer[J].Breast J,2013,19(2):180-188.doi:10.1111/tbj.12071.

引证文献5

二级引证文献12

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部